Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02705989
Registration number
NCT02705989
Ethics application status
Date submitted
7/03/2016
Date registered
11/03/2016
Date last updated
30/01/2019
Titles & IDs
Public title
Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects
Query!
Scientific title
A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects
Query!
Secondary ID [1]
0
0
IM014-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BMS-986195
Other interventions - Placebo
Placebo Comparator: Single Ascending Dose (SAD) - Single ascending dose of BMS-986195 or Placebo matching BMS-986195
Placebo Comparator: Multiple Ascending Dose(MAD) - Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
Placebo Comparator: Japanese-Multiple Ascending Dose(MAD) - Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
Experimental: Relative Bioavailability with Food Effects (Open Label) -
Treatment: Drugs: BMS-986195
Specified dose on specified day
Other interventions: Placebo
Specified dose on specified day
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability of single oral dose of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Up to 8 days during and after last dose
Query!
Primary outcome [2]
0
0
Safety and tolerability of multiple oral doses of BMS-986195 as determined by medical review of adverse event reports, vital sign measurements, electrocardiograms (ECGs), and results of physical examination and laboratory tests
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Up to 21 days during and after last dose
Query!
Eligibility
Key inclusion criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
- Body Mass Index(BMI) of 18 to 32 kilograms/meter^2
- Healthy male and female, first generation Japanese with confirmed paternal and
maternal Japanese ancestry, 18-55 years old, whose residency outside of Japan does not
exceed 10 years with a BMI of 18-30 kilograms/meter^2 inclusive.
- Women must not be pregnant or breastfeeding
- Women of Childbearing Potential (WOCBP) must agree to follow instructions for
method(s) of contraception for the duration of treatment with study drug plus 14 days
or longer if required.
- Males who are sexually active with WOCBP must agree to follow instructions for
method(s) of contraception for the duration of treatment with study drug plus 14 days
or longer if required.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Any significant acute or chronic medical illness
- Known or suspected autoimmune disorder, including but not limited to rheumatoid
arthritis, fibromyalgia, systemic lupus erythematosis, polymyalgia rheumatica, giant
cell arteritis, Behcet's disease, dermatomyositis, multiple sclerosis, moderate to
severe asthma, any autoimmune vasculitis, autoimmune hepatitis, or any other active
autoimmune disease for which a subject requires medical follow-up or medical treatment
- Any history of known or suspected congenital or acquired immunodeficiency state or
condition that would compromise the subject's immune status (example: history of
splenectomy)
- Presence of any factors that would predispose the subject to develop infection e.g.,
rectal fissures, poor dentition, open skin lesions, and presence of preexisting skin
conditions that increase risks for injection site complications e.g. Behcet's Disease,
Psoriasis, pustular dermatoses
- Any history or risk for tuberculosis (TB)
Other protocol defined inclusion/exclusion criteria could apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
18/08/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
439
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Local Institution - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3004 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics,
and pharmacodynamics following single and multiple ascending oral doses of BMS-986195 in
healthy subjects, and to assess the relative bioavailability of two formulations of
BMS-986195 with or without food.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02705989
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02705989
Download to PDF